Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058133 | 1.00 | TRPM8 (0.52) | TRPM8HCRTR1HCRTR2HDAC8GPR139 | |
| SCHEMBL3058136 | 0.88 | HCRTR1 (0.51) | TRPM8HCRTR1HCRTR2HDAC8GPR139 | |
| SCHEMBL3048416 | 0.88 | HCRTR1 (0.51) | TRPM8HCRTR1HCRTR2HDAC8GPR139 | |
| SCHEMBL3049767 | 0.87 | HCRTR1 (0.47) | TRPM8HCRTR1HCRTR2GPR139KMT2A | |
| SCHEMBL3058113 | 0.87 | HCRTR1 (0.47) | TRPM8HCRTR1HCRTR2GPR139KMT2A | |
| SCHEMBL3046975 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2MRGPRX4KMT2AKAT6A | |
| SCHEMBL3058130 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2MRGPRX4KMT2AKAT6A | |
| SCHEMBL3058232 | 0.84 | TRPM8 (0.49) | TRPM8HDAC8EPHX1 | |
| SCHEMBL3060247 | 0.84 | TRPM8 (0.49) | TRPM8HDAC8EPHX1 | |
| SCHEMBL3053241 | 0.83 | KMT2A (0.51) | HCRTR1HCRTR2KMT2AKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | TRPM8 1326/4885HCRTR1 3230/4885HCRTR2 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.